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We have reported that some lectins act as agonists of toll-like receptors (TLRs) and 
have immunomodulatory properties. The plant lectin ArtinM, for example, interacts with 
N-glycans of TLR2, whereas other lectins of microbial origin interact with TLR2 and 
TLR4. Expression of the receptors on the surface of antigen-presenting cells exposes 
N-glycans that may be targeted by lectins of different structures, specificities, and 
origins. In vitro, these interactions trigger cell signaling that leads to NF-κB activation 
and production of the Th1 polarizing cytokine IL-12. In vivo, a same sequence of 
events follows the administration of an active lectin to mice infected with an intra-
cellular pathogen, conferring resistance to the pathogen. The lectins of the human 
pathogens Toxoplasma gondii (TgMIC1 and TgMIC4) and Paracoccidioides brasiliensis 
(Paracoccin), by recognition and activation of TLR2 and TLR4, induce cell events and 
in vivo effects comparable to the promoted by the plant lectin ArtinM. In this article, we 
highlight these two distinct mechanisms for activating antigen-presenting cells. On the 
one hand, TLRs act as sensors for the presence of conventional pathogen-associated 
molecular patterns, such as microbial lipids. On the other hand, we showed that TLR-
mediated cell activation might be triggered by an alternative way, in which lectins bind 
to TLRs N-glycans and stimulate cells to increase the expression of pro-inflammatory 
cytokines. This process may lead to the development of new pharmaceutical tools 
that promote protective immune responses directed against intracellular pathogens 
and tumors.
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Toll-like receptors (TLRs) are pattern recognition receptors of the innate immune system (1–3). 
These receptors are Class 1 transmembrane proteins that recognize conserved structures associ-
ated with pathogenic microorganisms, collectively designated as pathogen-associated molecular 
patterns (PAMPs). PAMPs include the bacterial glycolipid LPS, peptidoglycans, and DNA with 
unmethylated CpG motifs (3). Recognition of PAMPs by TLRs triggers cell signaling and activation, 
which leads to potent antimicrobial responses and enables the initiation of adaptive Th1 immunity 
(4, 5). Because it is a desirable response in many circumstances, TLR agonists capable of activating 
protective mechanisms of the innate immune system are being investigated as possible prophylactic 
or therapeutic agents to combat infectious or neoplastic diseases (6–9).
It is well established that the architecture of the TLR ectodomains, particularly the solenoidal 
structure adopted by the leucine-rich repeats (LRR), confers specific recognition of these highly 
tabLe 1 | Plant and pathogens lectins reported to interact with toll-like receptors (TLRs).
source Lectin carbohydrate specificity target reference
Plant lectins Artocarpus heterophyllus ArtinM Manα1-3[Manα1-6]Man TLR2/1 and 2/6 
+CD14a
(15, 19, 20)
Canavalia ensiformis Concanavalin A Man/Glc (Man>Glc>GlcNAc) TLR2/6 (21)
Viscum album coloratum Korean mistletoe lectin 
(KML-C)
Terminal Gal and GalNAc residues TLR4 (22)
Phaseolus vulgaris Phytohemagglutinin-L 
(PHA-L)
Galβ1,4GlcNAcβ1,2(Galβ1,4GlcNAcβ1,6Man) TLR2/6, 4, and 5 (21)
Glycine max Soybean agglutinin GalNAc>Gal (terminal Gal and GalNAc residues) TLR4 (21)
Arachis hypogea Peanut agglutinin Gal(Galβ1,3GalNAc) (terminal Gal residue) TLR4 (21)
Triticum vulgaris Wheat germ agglutinin Man/Glc (Man>Glc>GlcNAc) TLR2/6, 5, 7, and 8 (21)
Pathogens 
lectins
Paracoccidioides 
brasiliensis
Paracoccin βGlcNAc14βGlcNAc14GlcNAc TLR2/1, 2/6, and 4 (14)
Toxoplasma gondii T. gondii microneme 1 NeuAcα-3Galβ-4GlcNAcβ-3Galβ-3GlcNAc (terminal 
NeuAc residue)
TLR2/1, 2/6, and 4 (23)
T. gondii T. gondii microneme 4 Galβ-3GalNAcβ-4Galβ-4Glc (terminal Gal residue) TLR2/1, 2/6, and 4 (23)
Entamoeba histolytica Gal/GalNAc lectin Terminal Gal/GalNAc residue TLR2 and 4 (16)
aArtinM interaction with glycans N-linked to the co-receptor CD14 is required for induction of TLR2 activation (20).
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diverse PAMPs. These recognition processes depend on the 
PAMP structure, the type of TLR involved, the formation of 
specific heterodimers, and the participation of co-receptors (10, 
11). Here, we highlight an alternative mode of TLR signaling 
activation in which the receptors instead of recognizing PAMPs 
are activated by sugar binding lectins. Lectins are ubiquitous 
proteins with reversible and specific carbohydrate recognition 
activity. By interacting with glycoproteins such as the TLRs 
on cell surfaces, lectins mediate diverse biological and cellular 
processes (12).
Toll-like receptor ectodomains are modified by at least four 
(TLR2) and as many as 9 N-linked glycans (TLR4) (13). These 
N-glycans play a role not only in biosynthesis and trafficking but 
also the triggering of TLR signal transduction. TLR N-glycans 
can be targeted by the carbohydrate recognition domain (CRD) 
of lectins, directly or indirectly initiating receptor activation 
(14–16). Lectin binding induces cell signaling and the release 
of pro-inflammatory cytokines, which can mimic the responses 
promoted by PAMPs recognition. Thus, these lectins acting 
through their CRD are potent TLRs agonists.
Pathogen-associated molecular pattern ligands of TLR2 and 4 
bind to receptors at the cell surface and induce dimerization of 
the ectodomains. This causes concerted conformational changes 
leading to homodimerization of the cytosolic TIR domains, and 
recruitment of downstream signal transducers, notably MyD88 
(17). It is likely that the binding of plant and pathogen lectins to 
receptor glycans is able to induce an equivalent activation process 
although this has not yet been experimentally verified. However, 
it is known that other non-canonical agonists such as nickel ions 
and cationic lipids stabilize the homodimerization interface that 
forms between the lateral surfaces of the receptor ectodomains 
(18) and lectins may have a similar mechanism of action. It 
is clear that lectins induce production of pro-inflammatory 
cytokines such as IL-6 and IL-8, but transcriptomic analysis has 
not been reported. RNASeq experiments currently underway 
should reveal how the transcriptional program elicited by lectins 
compares with that of PAMP ligands and whether this constitutes 
an endogenous alternative TLR pathway.
The first evidence for this alternative TLR activation mecha-
nism was provided by the response of innate immune cells to the 
plant lectin ArtinM (19). ArtinM is a mannose-binding jacalin-
related lectin that has been studied extensively by our research 
group. This lectin recognizes the N-glycan modifications of 
both TLR2 and the co-receptor CD14, promoting the assembly 
of an activation complex on the plasma membrane (15). TLR2 
has four N-glycosylation sites in its ectodomain, all of them 
modified by sugar chains, whose structures are still unknown. 
The glycan-site 1 is located on the convex surface of the LRR 
solenoid, exposed to solvent. Sites 2 and 3 are on the concave 
surface, also in positions that are solvent exposed. By contrast, 
site 4 is located on the terminal residue of the LRR16, which 
forms part of the inner surface of the solenoid, in a sterically 
restricted position. Interestingly, this fourth site is the only one 
that is conserved in receptors of all studied species (13). TLR2 
heterodimerization with TLR1 or TLR6, which occurs as part of 
the activation process, does not interfere with cellular responses 
promoted by ArtinM (15). This alternative activation pathway 
also occurs in response to other plant lectins, as well as to lectins 
derived from human pathogens. Table 1 summarizes the lectins 
reported to bind TLRs.
Paracoccin (PCN), a lectin derived from Paracoccidioides 
brasiliensis, also exerts immunomodulatory activities due to its 
Figure 1 | Glycans N-linked to TLR2, expressed on the surface of antigen-presenting cells, are targeted by carbohydrate recognition domain (CRD) of some 
lectins. The established interactions are followed by intracellular signaling and production of cytokines. Fully glycosylated TLR2 molecules can be targeted by lectins 
CRDs (shown at the right side of the figure), besides recognizing pathogen-associated molecular patterns (PAMPs) and synthetic ligands. Either interaction induces 
activation of NF-κB signaling pathway and production of cytokines. Most constructed TLR2 glycomutants (exhibiting isolated or combined elimination of N-glycans) 
preserve the capacity to recognize PAMPs, whereas some of the glycomutants become selectively unresponsive to a specific lectin stimulus (shown at the left side 
of this figure). This approach allows defining which N-glycans are critically required to trigger TLR2 activation by a lectin. In this illustration, the TLR2 N-glycans 
(numbered 1–4 and linked to Asn116, Asn199, Asn416, and Asn442) are not rigorously localized in the TLR2 backbone. For a more realistic representation of 
N-glycans position on TLR2, see the article authored by Weber et al. (13).
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interaction with both TLR4 and TLR2 N-glycans. Recent studies 
have identified the TLR2 N-glycans that are required for trig-
gering responses to the PCN stimulus. The investigation used 
TLR2 mutants generated by sequentially removing, through 
site-directed mutagenesis, all four Asn–X–Ser/Thr sequons. 
The co-transfection of both a mutated-TLR2 and the NF-κB-
reporter gene into HEK293 human cells, identified N-glycans 
that are necessary for mediating responses to the PCN stimulus, 
in comparison with the response mediated by fully glycosylated 
TLR2 (14). Interestingly, only the TLR2 N-glycan linked to site 4 
of the peptide bone was demonstrated as required for the lectin 
activity, demonstrating that PCN critically targets the fourth 
N-glycan to induce TLR2-mediated cell activation. Site 4 is the 
most conserved and least accessible among all TLR2 sites of 
N-glycosylation (13). Interestingly, all the TLR2 glycomutants 
could mediate cell activation in response to a classical agonist 
such as PAM3CsK4 (Figure 1).
We have also studied a pair of lectins, namely, T. gondii 
microneme 1 (TgMIC1) and T. gondii microneme 4 (TgMIC4), 
originally contained into Toxoplasma gondii microneme apical 
vesicles and early secreted during the process of host cells inva-
sion. These lectins are part of the TgMIC1/TgMIC4/TgMIC6 
complex, supported on the parasite surface by TgMIC6, 
which allows the exposition of TgMIC1 and TgMIC4 CRDs to 
interact with carbohydrate ligands (glycans with sialic acid and 
d-galactose on terminal position, respectively) on the host cells. 
The lectins’ interactions with macrophages and dendritic cells 
are established by the recognition of TLR2 and TLR4 N-glycans 
and result in modulation of the immune response toward the 
Th1 axis. Sardinha-Silva et al. (23) have recently demonstrated 
the importance of these lectins for the induction of early IL-12 
production in T. gondii infection. Concerning the discrimination 
of which TLR2 N-glycans are targeted by TgMIC1 and TgMIC4, 
those occupying positions 2, 3, and 4, impact the TgMIC1–
TLR2 interaction. On the other hand, TgMIC4 requires the 
TLR2 N-glycans linked to the sites 3 and 4 to interact with the 
receptor (23).
The characterization of TLRs as targets of recognition by 
exogenous agents opens new avenues for the design of pharma-
ceutical tools. Indeed, lectins or biomimetic lectins can be used 
as TLR agonists to improve immune responses to severe infec-
tions, especially in immunosuppressed patients, or as antitumor 
agents. Lectins might also be used as adjuvants that, associated 
with conventional treatment, can boost Th1 and Th17 immune 
responses (24, 25), which are both required to overcome fungal 
diseases (26). A priority for future research is to define the 
molecular mechanisms by which pathogen lectins active innate 
responses.
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In conclusion targeting of TLRs by lectins creates a new 
opportunity to therapeutically manipulate the immune response.
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